Deutsche Bank raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $24.00 (from $21.00) while maintaining a Buy rating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Halozyme Therapeutics (HALO) PT Raised to $19 at BMO CapitalFebruary 21, 2018 8:42 AM Halozyme Therapeutics (HALO) PT Raised to $22 at JPMorganFebruary 21, 2018 7:24 AM Halozyme Therapeutics (HALO) PT Raised to $21 at Canaccord GenuityFebruary 21, 2018 5:12 AM Halozyme Therapeutics (HALO) PT Raised to $21 at JMP SecuritiesFebruary 21, 2018 4:34 AM After-Hours Stock Movers 02/20: (TTPH) (LPSN) (VRSK) Higher; (RCII) (CATM) (LC) Lower (more...)February 20, 2018 6:16 PM Halozyme Therapeutics (HALO) Tops Q4 EPS by 13c; Reiterates OutlookFebruary 20, 2018 4:07 PM Halozyme Reports Fourth Quarter And Full-Year 2017 ResultsFebruary 20, 2018 4:05 PM